Lab
Centracare Health Systems
Centracare Health Systems was paid $9.41M by Medicaid between Jan 2018 and Dec 2024, across 148 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 31% of everything it billed.
33Billing provider infoCENTRACARE HEALTH SYSTEMS
SAINT CLOUD, MN 56303
SAINT CLOUD, MN 56303
33aNPI1326097833assigned 05/10/2006
33bProvider typeClinical Medical Laboratory
28Total paid$9.41M
24GClaims555,797
24DCodes billed148
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Minnesota
Rank by total paid#8 of 69
Median peer was paid$48K
This provider vs. median195×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BLAIR, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,147 | $152K | |
| 2019 | 49,672 | $548K | |
| 2020 | 48,604 | $920K | |
| 2021 | 115,620 | $2.79M | |
| 2022 | 107,187 | $2.15M | |
| 2023 | 109,104 | $1.58M | |
| 2024incomplete | 84,463 | $1.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 31% | 42,247 | 33,606 | $2.90M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 8.5% | 36,456 | 29,835 | $799K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.6% | 18,176 | 17,803 | $435K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.3% | 12,270 | 11,983 | $401K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.2% | 12,241 | 11,980 | $400K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.8% | 26,339 | 25,761 | $359K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.9% | 12,042 | 11,890 | $277K |
| 88142 | 2.3% | 11,002 | 10,914 | $219K | |
| 80061 | Lipid panel | 2.3% | 19,656 | 19,299 | $215K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.3% | 31,234 | 28,644 | $214K |
| 86803 | 1.8% | 12,812 | 12,682 | $172K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.6% | 4,819 | 4,780 | $151K |
136 more codes
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.6% | 3,807 | $150K |
| 87506 | 1.5% | 623 | $144K | |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 39,995 | $140K |
| 80053 | Comprehensive metabolic panel | 1.5% | 17,106 | $140K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.5% | 16,565 | $139K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.4% | 18,652 | $128K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 20,754 | $123K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 2,383 | $116K |
| 83970 | 1.2% | 3,019 | $111K | |
| 86780 | <1% | 7,384 | $91K | |
| 82607 | <1% | 6,295 | $84K | |
| 82728 | <1% | 5,914 | $73K | |
| 87070 | <1% | 9,840 | $73K | |
| 85610 | <1% | 11,316 | $49K | |
| 80050 | General health panel | <1% | 974 | $46K |
| 87186 | <1% | 5,721 | $44K | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 9,346 | $42K |
| 87340 | <1% | 4,136 | $40K | |
| 0352U | <1% | 282 | $39K | |
| 84153 | <1% | 2,225 | $38K | |
| 83550 | <1% | 5,494 | $38K | |
| 83735 | <1% | 6,949 | $37K | |
| 83540 | <1% | 6,121 | $35K | |
| 84439 | <1% | 4,355 | $35K | |
| 82670 | <1% | 1,179 | $31K | |
| 84702 | <1% | 2,067 | $31K | |
| 86140 | <1% | 6,625 | $30K | |
| 82570 | <1% | 6,698 | $30K | |
| 84481 | <1% | 1,752 | $27K | |
| 80306 | <1% | 1,748 | $26K | |
| 87077 | <1% | 3,109 | $26K | |
| 88342 | <1% | 341 | $25K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 916 | $25K |
| 86762 | <1% | 1,707 | $24K | |
| 83001 | <1% | 1,233 | $22K | |
| 86003 | <1% | 1,768 | $21K | |
| 82043 | <1% | 3,846 | $21K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,246 | $20K |
| 87480 | <1% | 1,045 | $20K | |
| 87660 | <1% | 1,045 | $20K | |
| 87510 | <1% | 1,042 | $19K | |
| 84146 | <1% | 1,086 | $19K | |
| 82746 | <1% | 1,447 | $19K | |
| 87493 | <1% | 594 | $19K | |
| 85027 | <1% | 3,033 | $17K | |
| 86706 | <1% | 1,551 | $16K | |
| 81001 | <1% | 6,367 | $16K | |
| 82248 | <1% | 3,411 | $16K | |
| 84403 | <1% | 651 | $15K | |
| 80076 | <1% | 2,119 | $14K | |
| 84144 | <1% | 659 | $13K | |
| 86850 | <1% | 1,436 | $13K | |
| 86769 | <1% | 319 | $12K | |
| 86038 | <1% | 1,053 | $12K | |
| 83880 | <1% | 302 | $12K | |
| 83655 | <1% | 1,036 | $12K | |
| 87209 | <1% | 648 | $11K | |
| 84100 | <1% | 3,040 | $11K | |
| 82947 | <1% | 2,920 | $11K | |
| 87625 | <1% | 275 | $10K | |
| 83516 | <1% | 673 | $10K | |
| 80074 | <1% | 209 | $10K | |
| 82565 | <1% | 2,687 | $10K | |
| 85018 | <1% | 4,695 | $9K | |
| 83002 | <1% | 528 | $9K | |
| 88304 | <1% | 298 | $9K | |
| 87205 | <1% | 2,190 | $8K | |
| 86200 | <1% | 671 | $8K | |
| 84460 | <1% | 1,469 | $7K | |
| 87420 | <1% | 479 | $7K | |
| 87150 | <1% | 227 | $6K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,018 | $6K |
| 87177 | <1% | 648 | $6K | |
| 86787 | <1% | 421 | $5K | |
| 82784 | <1% | 541 | $5K | |
| 83690 | <1% | 798 | $5K | |
| 86431 | <1% | 991 | $5K | |
| 80164 | <1% | 583 | $5K | |
| 84156 | <1% | 1,508 | $5K | |
| 81003 | <1% | 2,464 | $5K | |
| 87329 | <1% | 386 | $5K | |
| 85007 | <1% | 1,301 | $4K | |
| 85652 | <1% | 1,761 | $4K | |
| 84450 | <1% | 895 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 98 | $4K |
| 84132 | <1% | 936 | $4K | |
| 83721 | <1% | 379 | $3K | |
| 82533 | <1% | 227 | $3K | |
| 86900 | <1% | 1,102 | $3K | |
| 86901 | <1% | 1,097 | $3K | |
| 82785 | <1% | 191 | $3K | |
| 82550 | <1% | 463 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 46 | $2K |
| 84550 | <1% | 568 | $2K | |
| 86141 | <1% | 175 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 273 | $2K |
| 80069 | <1% | 289 | $2K | |
| 86480 | <1% | 40 | $2K | |
| 87075 | <1% | 227 | $2K | |
| 86376 | <1% | 140 | $2K | |
| 86705 | <1% | 162 | $2K | |
| 84402 | <1% | 83 | $2K | |
| 88341 | <1% | 16 | $2K | |
| 82310 | <1% | 414 | $1K | |
| 87338 | <1% | 91 | $1K | |
| 85379 | <1% | 133 | $1K | |
| 84484 | <1% | 104 | $1K | |
| 80051 | <1% | 296 | $1K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 167 | $997.33 |
| 81015 | <1% | 279 | $789.37 | |
| 81025 | <1% | 85 | $703.24 | |
| 86618 | <1% | 34 | $629.19 | |
| 82150 | <1% | 107 | $597.88 | |
| 86592 | <1% | 162 | $525.10 | |
| 87102 | <1% | 67 | $519.75 | |
| 86364 | <1% | 34 | $500.91 | |
| 80178 | <1% | 100 | $471.80 | |
| 88302 | <1% | 13 | $422.10 | |
| 82040 | <1% | 93 | $414.43 | |
| 85049 | <1% | 54 | $227.44 | |
| 83630 | <1% | 12 | $203.00 | |
| 87430 | <1% | 58 | $183.82 | |
| 84165 | <1% | 15 | $178.26 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 1,233 | $161.59 |
| 87210 | <1% | 27 | $158.79 | |
| 82140 | <1% | 16 | $147.94 | |
| 82950 | <1% | 28 | $136.78 | |
| 85048 | <1% | 59 | $128.88 | |
| 85730 | <1% | 24 | $117.67 | |
| 82247 | <1% | 29 | $116.94 | |
| 84520 | <1% | 98 | $116.76 | |
| 83930 | <1% | 14 | $112.36 | |
| 82465 | <1% | 44 | $110.75 | |
| 83718 | <1% | 30 | $108.42 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 0% | 17 | $0.00 |
| 86677 | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBLAIR, MICHAEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| ST. Cloud Hospital | Saint Cloud, MN | $53.43M |
| Centracare Clinic | St Cloud, MN | $20.93M |
| Centracare Clinic | St Cloud, MN | $19.28M |
| Centracare Health System | Big Lake, MN | $12.82M |
| Carris Health LLC | Willmar, MN | $12.39M |
| Centracare Health System | Saint Cloud, MN | $9.06M |
| Carris Health LLC | Willmar, MN | $8.27M |
| Centracare Clinic | Saint Cloud, MN | $6.96M |
| Centracare Health System - Long Prairie | Long Prairie, MN | $6.86M |
| Centracare Health System-Nr LLC | Monticello, MN | $6.73M |
| Centracare Clinic | Sartell, MN | $6.11M |
| ST. Cloud Hospital | Saint Cloud, MN | $5.16M |
| Carris Health - Redwood LLC | Redwood Falls, MN | $4.74M |
| ST. Cloud Hospital | St Cloud, MN | $4.44M |
| Centracare Health System - Sauk Centre | Sauk Centre, MN | $4.19M |
| Centracare Health System - Melrose | Melrose, MN | $4.05M |
| Centracare Clinic | Saint Cloud, MN | $3.58M |
| Centracare Clinic | Saint Cloud, MN | $2.83M |
| Carris Health, LLC | Willmar, MN | $2.82M |
| ST. Cloud Hospital | Sauk Rapids, MN | $2.53M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.